Prognostic factors for the outcome of methotrexate treatment in rheumatoid arthritis.
Kolarz
G
G
Institute for Rheumatology, Baden, Austria.
Mayrhofer
F
F
Peichl
P
P
Posch
E
E
Scherak
O
O
Singer
F
F
Thumb
N
N
Wottawa
A
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000906:Antibodies / Q000032:analysis; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007375:Interleukin-1 / Q000378:metabolism; D016209:Interleukin-8 / Q000276:immunology; D008297:Male; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D011379:Prognosis; D016896:Treatment Outcome
D000906:Antibodies; D007375:Interleukin-1; D016209:Interleukin-8; D008727:Methotrexate